- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BGNE
Recent news which mentions BGNE
From Benzinga
Why Are BeiGene Shares Trading Lower Today
July 11, 2023
From Benzinga
From Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
June 30, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
From Benzinga
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
May 25, 2023
From Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
From Benzinga
What's Going On With Immix Biopharma Stock Today
May 03, 2023
From Benzinga
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
From Motley Fool
7 Biotech Stocks That Could Cure Your Portfolio Woes
April 19, 2023
From InvestorPlace
From Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
From Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023
From Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
April 11, 2023
From Benzinga
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
March 13, 2023
From Benzinga
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
February 27, 2023
From Benzinga
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
January 26, 2023
From Motley Fool
From Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
January 20, 2023
Tickers
BGNE
From Benzinga
One of the greatest cancer drugs ever has suddenly lost its edge. This is why it was vulnerable.
January 18, 2023
From MarketWatch
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.